Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in several upcoming virtual investor conferences. Notable events include the 2021 Jefferies London Healthcare Conference on November 18, the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, the Evercore ISI HeathCONx Conference on December 1, and the JMP Securities Hematology and Oncology Summit on December 6. Links to live audio webcasts and replays will be available on BioCryst's website. The company focuses on developing innovative medicines for rare diseases.
BioCryst Pharmaceuticals announced promising long-term efficacy and safety data for ORLADEYO (berotralstat) at the 2021 ACAAI Annual Scientific Meeting. The APeX-S study revealed patients switching from injectable prophylactic therapies experienced over 80% attack-free months. ORLADEYO demonstrated low attack rates, with a median of 0.0 attacks per month over 12 months. Patient satisfaction improved significantly, with marked increases in treatment convenience. These results position ORLADEYO as a transformative option for hereditary angioedema (HAE) patients.
BioCryst Pharmaceuticals (BCRX) reported Q3 2021 revenue of $41.0 million, up from $6.1 million year-over-year, driven by ORLADEYO® (berotralstat) net revenue of $37.0 million. The company projects full-year 2021 ORLADEYO revenue between $115 million and $120 million. Strong patient demand persists, with significant physician adoption and near-complete payer coverage. However, R&D expense rose to $50.0 million, and the net loss was $58.8 million, or $0.33 per share. Cash and investments were $203.9 million as of September 30, 2021.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement options for 95,500 shares to 10 new employees as of October 29, 2021. The exercise price is set at $14.93, aligning with the closing stock price on the grant date. The options vest in four annual installments, contingent on continued employment, and have a term of 10 years. BioCryst is focused on developing innovative treatments for rare diseases, with notable products including ORLADEYO® and RAPIVAB®.
BioCryst Pharmaceuticals (Nasdaq:BCRX) has appointed Jinky Ang Rosselli as chief data and insights officer. In this capacity, she will lead a global team to enhance the company’s data science and analytics capabilities, aiming to inform strategic decisions. Rosselli, previously vice president of global business analysis, has a strong background in data-driven insights, which has contributed to the successful launch of ORLADEYO® (berotralstat). Her leadership is expected to further optimize BioCryst's commercial infrastructure and drive future innovations across various disease-related pipelines.
BioCryst Pharmaceuticals (BCRX) will present four abstracts, including a Distinguished Industry Oral Abstract, at the American College of Allergy, Asthma & Immunology (ACAAI) meeting from November 4-8, 2021, in New Orleans. The presentations will focus on ORLADEYO® (berotralstat) for hereditary angioedema (HAE) treatment. Key findings include low HAE attack rates in patients and high patient satisfaction when switching from injectables to ORLADEYO. The company continues to support the transition to oral prophylactic treatments for HAE.
BioCryst Pharmaceuticals (BCRX) announced plans to report its third quarter 2021 financial results on November 3, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the call via phone or a live webcast on the company’s website. BioCryst focuses on discovering novel, oral medications for rare diseases, with products like ORLADEYO approved in multiple regions and ongoing development programs for other treatments, including BCX9930 and BCX9250.
BioCryst Pharmaceuticals (BCRX) has granted inducement options to nine new employees for a total of 178,500 shares of its common stock as of September 30, 2021. The options have an exercise price of $14.37 per share, matching the stock's closing price on that date. Vesting occurs in four equal installments annually, contingent on continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and supports BioCryst's commitment to attracting talent in the rare disease treatment sector.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the 2021 Cantor Virtual Healthcare Conference on September 28, 2021, at 2:00 p.m. ET. Investors can access the live audio webcast and replay on the company's website. BioCryst specializes in developing novel oral medicines for rare diseases, with approved products such as ORLADEYO® for certain medical conditions. The company is also working on several other treatments, including BCX9930 for complement-mediated diseases and galidesivir for viral infections.
BioCryst Pharmaceuticals (Nasdaq:BCRX) has appointed Dr. Amy McKee to its board of directors, enhancing its regulatory expertise. Dr. McKee, a former deputy center director at the FDA's Oncology Center of Excellence, brings over a decade of experience in drug development and regulatory strategy. She will aid in advancing the company's pivotal trials for BCX9930, aimed at treating PNH and other complement-mediated diseases. This strategic move is expected to strengthen BioCryst's leadership as it continues to develop innovative treatments for rare diseases.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
